机械通气患者既存肌少症的患病率与预后价值:系统评价与荟萃分析
该系统评价与荟萃分析检索MEDLINE、Embase和Cochrane图书馆截至2021年12月发表的文章,最终纳入17项研究、3582例机械通气患者。既存肌少症的合并患病率为43.0%(95%CI 34.0-51.0%;I²=96.7%)。与无肌少症患者相比,肌少症患者死亡率升高(OR 2.13;95%CI 1.70, 2.67;I²=45.0%),机械通气时间(MD=1.22;95%CI 0.39, 2.05;I²=97.0%)、ICU住院时间(MD=1.31;95%CI 0.43, 2.19;I²=97.0%)和住院时间(MD=2.73;95%CI 0.58, 4.88;I²=98.0%)均延长。作者认为肌少症在机械通气患者中患病率较高且对预后有负面影响,但需要进一步大规模高质量前瞻性队列研究。
要点
- 机械通气患者既存肌少症合并患病率为43.0%(95%CI 34.0-51.0%;I²=96.7%)。
- 肌少症与死亡率升高相关:OR 2.13(95%CI 1.70, 2.67;I²=45.0%)。
- 肌少症与机械通气时间延长相关:MD=1.22(95%CI 0.39, 2.05;I²=97.0%)。
- 肌少症与ICU住院时间延长相关:MD=1.31(95%CI 0.43, 2.19;I²=97.0%)。
- 肌少症与住院时间延长相关:MD=2.73(95%CI 0.58, 4.88;I²=98.0%)。
适用人群与场景
- 机械通气患者(纳入17项研究、共3582例患者)。
诊断标准与关键阈值
- 肌少症患病率按原始研究作者的定义判定。
研究设计与关键结果
- 研究类型:系统评价与荟萃分析;检索MEDLINE、Embase和Cochrane图书馆截至2021年12月发表的文章,初检1333项研究,17项符合定量分析标准,共3582例机械通气患者。
- 既存肌少症合并患病率为43.0%(95%CI 34.0-51.0%;I²=96.7%)。
- 肌少症与死亡率升高相关:OR 2.13(95%CI 1.70, 2.67;I²=45.0%)。
- 肌少症与机械通气时间延长相关:MD=1.22(95%CI 0.39, 2.05;I²=97.0%)。
- 肌少症与ICU住院时间延长相关:MD=1.31(95%CI 0.43, 2.19;I²=97.0%)。
- 肌少症与住院时间延长相关:MD=2.73(95%CI 0.58, 4.88;I²=98.0%)。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析(纳入17项研究)。
- 局限:异质性高(患病率I²=96.7%;机械通气时间I²=97.0%;ICU住院时间I²=97.0%;住院时间I²=98.0%);作者指出需要进一步大规模高质量前瞻性队列研究。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sarcopenia is defined as age-related loss of muscle mass, strength, and/or function in the context of aging. Mechanical ventilation (MV) is one of the most frequently used critical care technologies in critically ill patients. The prevalence of preexisting sarcopenia and the clinical impact of its prognostic value on patients with MV are unclear. This review sought to identify the prevalence and prognostic value of preexisting sarcopenia on MV patient health outcomes.
METHODS: Relevant studies were identified by searching MEDLINE, Embase, and the Cochrane library and were searched for all articles published as of December 2021. The prevalence of sarcopenia was determined using the authors' definitions from the original studies. Comparisons were made between patients who did and did not have sarcopenia for prognostic outcomes, including mortality, the number of days of MV, the length of intensive care unit stay, and the length of hospital stay. Odds ratios (ORs) and weighted mean differences with 95% confidence intervals (CIs) were used for pooled analyses of the relationships between sarcopenia and prognostic outcomes.
RESULTS: The initial search identified 1333 studies, 17 of which met the eligibility criteria for the quantitative analysis, including 3582 patients. The pooled prevalence was 43.0% (95% CI 34.0-51.0%; I2 = 96.7%). The pooled analyses showed that sarcopenia was related to increased mortality (OR 2.13; 95% CI 1.70, 2.67; I2 = 45.0%), longer duration of MV (MD = 1.22; 95% CI 0.39, 2.05; I2 = 97.0%), longer days of ICU stay (MD = 1.31; 95% CI 0.43, 2.19; I2 = 97.0%), and hospital stay (MD 2.73; 95% CI 0.58, 4.88; I2 = 98.0%) in patients with MV.
CONCLUSION: The prevalence of sarcopenia is relatively high in patients with MV, and it will have a negative impact on the prognosis of patients. However, further, large-scale, high-quality prospective cohort studies are required.
参考来源
- Jiang T, Lin T, Shu X, et al. Prevalence and prognostic value of preexisting sarcopenia in patients with mechanical ventilation: a systematic review and meta-analysis. Crit Care. 2022. PMID: 35578299. doi:10.1186/s13054-022-04015-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。